newsfilter
← Latest News
GlobeNewswire·

Anteris’ DurAVR THV Demonstrates 1% Heart Failure Hospitalization, Single-Digit Gradients and No Valve-Related Deaths at 1 Year in Patients with Small Aortic Annuli

  • Anteris Technologies Global Corp. announced 1-year clinical & hemodynamic outcomes for the DurAVR Transcatheter Heart Valve (THV) in 100 patients with severe aortic stenosis & small aortic annuli.
  • At 1 year, only 1% of patients were hospitalized for heart failure, a rate lower than contemporary trials with current marketed products.
  • Hemodynamic performance showed a mean pressure gradient of 8.9 mmHg & mean effective orifice area (EOA) of 2.2 cm², with no moderate or severe paravalvular leak (PVL) observed.
  • 97% of patients remained free from moderate or severe prosthesis-patient mismatch (PPM) at 30 days, with no valve-related mortality reported through 1 year.
  • Symptomatic improvement was substantial, with NYHA class I/II patients increasing from 39% at baseline to 96% at 1 year.
  • The study cohort included complex patients with a mean STS-PROM score of 4.7%, 61% in NYHA class III/IV, & included cases of heavy calcification & bicuspid anatomy.
  • Cardiac magnetic resonance substudy data revealed a 24% regression in left ventricular mass at 1 year, indicating significant cardiac remodeling & unloading.
  • Clinical events at 1 year included 6% all-cause mortality, 3% stroke, & 9% new permanent pacemaker implantation.
  • Results were presented by Dr. Rishi Puri at PCR London Valves on November 22, 2026, via a late-breaking abstract titled "One-Year Clinical and Hemodynamic Outcomes of a Novel Biomimetic Balloon-Expandable THV in Small Aortic Annuli."
  • The DurAVR THV is currently under investigation in the pivotal PARADIGM Trial, a randomized head-to-head study enrolling approximately 1,000 patients in the US & Europe.
  • PARADIGM aims to assess non-inferiority on a primary composite endpoint of all-cause mortality, all stroke, & cardiovascular hospitalization at one year post-procedure.
  • DurAVR is a biomimetic, balloon-expandable valve made from single-piece molded ADAPT tissue, designed to replicate normal aortic blood flow & is intended for investigational use only.
Company
Anteris Technologies Pty Ltd
Keywords
Australian Stock Exchange:AVR.AX, Anteris Technologies Pty Ltd, Anteris Technologies, Late Breaking Clinical Trial, PCR London Valves, 1 Year Data 100 Patients, DurAVR THV, R Puri MD PhD